The proposed bill, known as the Patient Protection Act, seeks to enact section 3715.39 of the Revised Code, which aims to regulate the sale and prescription of certain drugs that can cause severe adverse effects. The bill defines "severe adverse effects" to include conditions such as death, hospitalization due to infection or hemorrhaging, organ failure, and sepsis. It prohibits retailers and terminal distributors of dangerous drugs from selling any drug available without a prescription if it causes severe adverse effects in more than five percent of users. Additionally, it restricts the sale of such drugs by mail and establishes specific conditions that prescribers must follow before issuing prescriptions for these drugs.

Under the bill, the director of health is tasked with determining which drugs cause severe adverse effects in more than five percent of users, in consultation with relevant state officials. The director will base this determination on insurance claims, patient reports, and data from the FDA. Furthermore, the director is required to maintain and publicly update a list of these drugs on the department of health's website. This legislation aims to enhance patient safety by ensuring that both the sale and prescription of potentially harmful drugs are closely monitored and regulated.